NYSE:OGNPharmaceuticals
Organon (OGN) Margin Hit To 3% Tests Bullish Earnings Recovery Story
Organon (OGN) has put Q1 2026 under the microscope with investors watching trailing numbers that show Q4 2025 revenue of US$1.5 billion, basic EPS of US$0.72 across the last twelve months, and a trailing net income of US$187 million after a large one off loss. Over recent quarters, the company has seen quarterly revenue move from US$1.59 billion in Q4 2024 to US$1.51 billion in Q4 2025, while basic EPS has ranged from US$0.34 in Q1 2025 up to US$1.39 in Q3 2024 and then to a loss of US$0.79...